Compare SLRC & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLRC | FULC |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 803.0M | 718.4M |
| IPO Year | 2007 | 2019 |
| Metric | SLRC | FULC |
|---|---|---|
| Price | $13.80 | $7.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $15.58 | ★ $16.38 |
| AVG Volume (30 Days) | 308.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.64 | $2.32 |
| 52 Week High | $17.26 | $15.74 |
| Indicator | SLRC | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 32.05 | 33.14 |
| Support Level | N/A | $7.40 |
| Resistance Level | $15.52 | $7.64 |
| Average True Range (ATR) | 0.38 | 0.65 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 0.00 | 6.49 |
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.